Back to results
US 7,018,990 B2Granted
Combination of a factor Xa inhibitor and clopidogrel
AssigneeBristol-Myers Squibb Company
InventorsPancras C. Wong, Robert M. Knabb
Life of this patent
Estimating the term…
Abstract
The present application describes methods of using a combination of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-5-[[4-[(2′-dimethylaminomethyl)imidazol-1′-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt, a factor Xa inhibitor, and Clopidogrel as anticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.
Claims20
A method for treating a thromboembolic disorder, comprising:
- administering, to a host in need of such treatment, a therapeutically effective amount of:
- (a) a first therapeutic agent which is 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-5-[[4-[(2′-dimethylaminomethyl)imidazol-1′-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt (Compound A) or a pharmaceutically acceptable salt form thereof;
- and,
- (b) a second therapeutic agent which is Clopidogrel or a pharmaceutically acceptable salt form thereof;
- wherein said first and second agents are administered in therapeutically effective amounts which provide a synergistic antithrombotic effect.
2 more elements
A pharmaceutical composition, comprising:
- (a) a first therapeutic agent which is 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-5-[[4-[(2′-dimethylaminomethyl)imidazol-1′-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt (Compound A) or a pharmaceutically acceptable salt form thereof;
- (b) a second therapeutic agent which is Clopidogrel or a pharmaceutically acceptable salt form thereof;
- and,
- (c) a pharmaceutically acceptable carrier;
- wherein said first and second therapeutic agents are present in amounts which provide a synergistic antithrombotic effect upon administration.
2 more elements
Dependencies are inferred from the claim text.